Please login to the form below

Not currently logged in

Calls for action on unlicensed medicines

Four European patient groups have called for more and improved measures against the use of unlicensed and off-label medicines, including the introduction of mandatory adverse event reporting

Four European patient groups have called for more and improved measures against the use of unlicensed and off-label medicines.

The European Alliance for Access to Safe Medicines (EAASM), the European Federation of Neurological Associations, the European Men's Health Forum and the European Depression Association all signed a statement demanding mandatory reporting by healthcare professionals of adverse events involving unlicensed and off-label use of medicines.

The groups want to establish the number of adverse events relating to unlicensed and off-label use of medicines and improve public awareness so that patients are aware when medicines are used in this way. Greater knowledge of the importance of reporting adverse events is also being encouraged.

The joint statement said there is an 'urgent need to address patient safety issues' regarding such use of medicines, with recent warnings from the US Food and Drug Administration (FDA) concerning a spate of serious eye infections in Florida related to the off-label use of an unlicensed medicine.

Jim Thomson, chair of the European Alliance for Access to Safe Medicines (EAASM) said the US authorities were only able to act on the issue due to obligatory adverse event reporting, and a similar process was needed in the EU.

He said: "In Europe it's a matter of chance as to whether the regulatory authorities are made aware of similar problems because there is no mandatory mechanism to report adverse events in medicines used this way."

All patient organisations involved in writing the statement are currently seeking meetings with European regulatory and professional bodies over the coming weeks to take their demands further.

20th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...